Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial

International Journal of Radiation Oncology Biology Physics

Volumn 84, Issue 3, 2012, Pages

  Berger, Adam C ^a,j   Winter, Kathryn ^b   Hoffman, John P ^c   Regine, William F ^d   Abrams, Ross A ^e   Safran, Howard ^f   Freedman, Gary M ^c   Benson III, Alan B ^g   MacDonald, John ^h   Willett, Christopher G ⁱ  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b RTOG Statistical Center   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f MIRIAM HOSPITAL   (United States)

^g NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^h ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j MOB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHEMORADIATION; CONFIDENCE INTERVAL; COX PROPORTIONAL HAZARD MODEL; GEMCITABINE; HAZARD RATIO; KAPLAN-MEIER METHOD; MEDIAN SURVIVAL; OVERALL SURVIVAL; PANCREATIC CANCERS; PANCREATIC HEAD; RADIATION THERAPY ONCOLOGY GROUPS; RANDOMIZED TRIAL; SERUM LEVELS; TUMOR MARKERS; UNIVARIATE;

BODY FLUIDS; DRUG PRODUCTS; QUALITY ASSURANCE; TUMORS;

PATIENT TREATMENT;

CA 19-9 ANTIGEN; FLUOROURACIL; GEMCITABINE; TUMOR MARKER;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL;

ANTIMETABOLITES, ANTINEOPLASTIC; CA-19-9 ANTIGEN; CHEMORADIOTHERAPY, ADJUVANT; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 84866731260     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.04.035     Document Type: Article

References (21)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2007 CA Cancer J Clin 57 2007 43 66
2. M.H. Kalser, and S.S. Ellenberg Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection Arch Surg 120 1985 899 903
3. J.H. Klinkenbijl, J. Jeekel, and T. Sahmoud Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group Ann Surg 230 1999 776 782
4. J.P. Neoptolemos, J.A. Dunn, and D.D. Stocken Adjuvant chemoradiotherapy and chemotherapy in resectable PC: a randomised controlled trial Lancet 358 2001 1576 1585
5. H. Oettle, S. Post, and P. Neuhaus Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of PC: a randomized controlled trial JAMA 297 2007 267 277
6. E. Beretta, A. Malesci, and A. Zerbi Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer Cancer 60 1987 2428 2431
7. J. Glenn, W.M. Steinberg, and S.H. Kurtzman Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas J Clin Oncol 6 1988 462 468
8. W.F. Regine, K.A. Winter, and R.A. Abrams Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial JAMA 299 2008 1019 1026
9. S.R.Z. Abdel-Misih, I. Hatzaras, and C. Schmidt Failure of normalization of CA 19-9 following resection for pancreatic cancer is tantamount to metastatic disease Ann Surg Oncol 18 2011 1116 1121
10. M.A. Tempero, E. Uchida, and H. Takasaki Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer Cancer Res 47 1987 5501 5503
11. R.C. Montgomery, J.P. Hoffman, and L.B. Riley Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas Ann Surg Oncol 4 1997 551 556
12. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
13. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163 170
14. D.R. Cox Regression models and life-tables J Royal Stat Soc Ser B (Methodological) 34 2 1972 187 220
15. A.C. Berger, M. Garcia Jr., and J.P. Hoffman Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704 J Clin Oncol 26 2008 5918 5922
16. H. Koprowski, Z. Steplewski, and K. Mitchell Colorectal carcinoma antigens detected by hybridoma antibodies Somatic Cell Genet 5 1979 957 971
17. R. Lamerz Role of tumour markers, cytogenetics Ann Oncol 10 suppl 4 1999 S145 S149
18. A.C. Berger, I.M. Meszoely, and E.A. Ross Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma Ann Surg Oncol 11 2004 644 649
19. T.J. Kinsella, Y. Seo, and J. Willis The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer Am J Clin Oncol 31 2008 446 453
20. N. Kondo, K. Murakami, and K. Uemura Prognostic impact of perioperative serum Ca 19-9 levels in patients with resectable pancreatic cancer Ann Surg Oncol 17 9 2010 2321 2329
21. R.A. Abrams, K.A. Winter, and W.F. Regine Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704-A phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas Int J Radiat Oncol Biol Phys 82 2012 809 816